Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Britannia Pharmaceuticals Ltd..
Recruitment status was  Not yet recruiting
Information provided by:
Britannia Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier:
First received: June 29, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Condition Intervention Phase
Parkinson's Disease
Drug: Apomorphine Nasal Powder
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Britannia Pharmaceuticals Ltd.:


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion Criteria:

  • hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00346827

Sponsors and Collaborators
Britannia Pharmaceuticals Ltd.
Principal Investigator: Richard Weiser, MB, MRCP Swansea Hospital, Swansea, Wales
  More Information

ClinicalTrials.gov Identifier: NCT00346827     History of Changes
Other Study ID Numbers: 20102D05 
Study First Received: June 29, 2006
Last Updated: June 29, 2006
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Netherlands: Medicines Evaluation Board (MEB)
Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Autonomic Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on May 04, 2016